SOURCE: Hamilton Thorne

Hamilton Thorne

March 31, 2016 13:00 ET

Hamilton Thorne to Present at The MicroCap Conference in Toronto Ontario

BEVERLY, MA and TORONTO, ON--(Marketwired - Mar 31, 2016) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today announced that David Wolf, President and CEO of Hamilton Thorne, will be presenting at The MicroCap Conference on Monday, April 11 at 3:30 p.m. (EDT) at the Philadelphia Hilton Toronto in Toronto, Ontario.

Mr. Wolf will be available for one-on-one meetings with the investment community on April 11th and 12th. Investors attending the conference who wish to meet with Mr. Wolf should contact Hamilton Thorne at ir@hamiltonthorne.com

The MicroCap Conference aims to bring together a very selective group of high quality companies and some of the best investors in the micro-cap space. Registration as well as one-on-one scheduling is available at www.microcapconf.com.

About Hamilton Thorne Ltd. (www.hamiltonthorne.com)

Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems that reduce cost, increase productivity, improve results and enable breakthroughs in the assisted reproduction, regenerative medicine and developmental biology research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities and provide high-end toxicology analyses. Hamilton Thorne's growing worldwide customer base consists of pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, animal breeding companies, and other commercial and academic research establishments, including Harvard, MIT, Yale, McGill, Oxford, Cambridge, the Smithsonian Institution, Charles River Labs, Covance, ABS Global, Sexing Technologies, Merck, Novartis, Pfizer, and Dow Chemical.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

Contact Information

  • For more information, please contact:
    David Wolf
    President & CEO
    Hamilton Thorne Ltd.
    978-921-2050
    Email Contact

    Michael Bruns
    CFO
    Hamilton Thorne Ltd.
    978-921-2050
    Email Contact